Shigella Conjugate Vaccine

Polysaccharide-protein conjugate vaccine targeting Shigella flexneri for diarrheal disease prophylaxis. Classified in HTS 3002.49.0050 as other immunological product from microbial cultures, modified biotechnologically for therapeutic use.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
๐Ÿ‡จ๐Ÿ‡ณChinaFreeโ€”Free
๐Ÿ‡ฒ๐Ÿ‡ฝMexicoFreeโ€”Free
๐Ÿ‡จ๐Ÿ‡ฆCanadaFreeโ€”Free
๐Ÿ‡ฉ๐Ÿ‡ชGermanyFreeโ€”Free
๐Ÿ‡ฏ๐Ÿ‡ตJapanFreeโ€”Free

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

3002Same rate: Free

If for smallpox

Specific viral vaccines like smallpox are enumerated separately.

2937.90Higher: 10% vs Free

If isolated hormone-based adjuvant only

Pure hormones shift to Chapter 29 organics, not immunological products.

3004.90Higher: 10% vs Free

If medicated with antibiotics

Mixed antibiotic-vaccine preparations fall under 3004 medicaments.

Not sure which classification is right?

Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.

Import Tips & Compliance

โ€ข Include conjugate linkage details in specs; FDA biologics surveillance applies

โ€ข Certify sterility and adjuvant absence if applicable; use insulated shippers

Related Products under HTS 3002.49.00.50

Malaria RTS,S Vaccine

Recombinant circumsporozoite protein-based vaccine with AS01 adjuvant for Plasmodium falciparum. HTS 3002.49.0050 as other protozoal culture-derived prophylactic.

Human Papillomavirus Recombinant Vaccine

VLP vaccine from HPV L1 protein expression for cervical cancer prevention. Classified HTS 3002.49.0050 as other viral biotechnological product.

Human Rotavirus Vaccine

A live attenuated oral vaccine containing reassortant rotaviruses for active immunization against rotavirus gastroenteritis in infants. Classified under HTS 3002.49.0050 as it is a vaccine for human use, other than those specifically enumerated elsewhere in heading 3002. It is prepared for prophylactic purposes via biotechnological processes.

Dengue Tetravalent Vaccine

A chimeric live-attenuated tetravalent vaccine protecting against all four dengue virus serotypes for endemic prevention. Falls under HTS 3002.49.0050 as an 'other' vaccine for human prophylactic use, not matching specific viral listings. Developed through biotechnological recombination.

Cholera Oral Vaccine

Inactivated oral vaccine with recombinant B-subunit and killed whole cells for cholera prevention in travelers. HTS 3002.49.0050 applies as an 'other' microbial culture-based vaccine for prophylactic human use. Not yeast-derived, fitting chapter exclusions.

Norovirus Virus-Like Particle Vaccine

Virus-like particle (VLP) vaccine mimicking norovirus capsids for gastrointestinal prophylaxis. HTS 3002.49.0050 covers this as other biotechnologically obtained similar product for human vaccination, excluding yeasts.